We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Arcus Biosciences Inc
9 own
4 watching
Current Price
$20.54
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,501.47M
52-Week High
36.13
52-Week Low
15.7
Average Volume
0.03M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,501.47M52-Week High36.1352-Week Low15.7Average Volume0.03MDividend Yield--P/E Ratio--What does the Arcus Biosciences Inc do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Read More
How much money does Arcus Biosciences Inc make?
News & Events about Arcus Biosciences Inc.
Zolmax
1month ago
Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) has been given a consensus recommendation of Moderate Buy by the ten research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on ...
Ticker Report
3 months ago
Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) has been assigned an average recommendation of Moderate Buy from the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have given a ...
Business Wire
5 months ago
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted four new employees options to purchase a total of 11,250 shares of the...
MarketWatch.com - GOOG
5 months ago
New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs...
Zolmax
5 months ago
Shares of Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) have been given an average rating of Moderate Buy by the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy ...
Frequently Asked Questions
Frequently Asked Questions
What is Arcus Biosciences Inc share price today?
Can Indians buy Arcus Biosciences Inc shares?
How can I buy Arcus Biosciences Inc shares from India?
Can Fractional shares of Arcus Biosciences Inc be purchased?
What are the documents required to start investing in Arcus Biosciences Inc stocks?
What is today’s traded volume of Arcus Biosciences Inc?
What is today’s market capitalisation of Arcus Biosciences Inc?
What is the 52-Week High and Low Range of Arcus Biosciences Inc?
What percentage is Arcus Biosciences Inc down from its 52-Week High?
What percentage is Arcus Biosciences Inc up from its 52-Week Low?
Current Price
$20.54
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.